116 related articles for article (PubMed ID: 36607949)
1. Cost-effectiveness of MicroRNA for Pancreatic Cancer Screening in Patients With Diabetes.
Kowada A
Pancreas; 2022 Sep; 51(8):1019-1028. PubMed ID: 36607949
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of Abdominal Ultrasound Versus Magnetic Resonance Imaging for Pancreatic Cancer Screening in Familial High-Risk Individuals in Japan.
Kowada A
Pancreas; 2020 Sep; 49(8):1052-1056. PubMed ID: 32769852
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes.
Wang L; Scott FI; Boursi B; Reiss KA; Williams S; Glick H; Yang YX
Clin Gastroenterol Hepatol; 2022 Sep; 20(9):1997-2004.e7. PubMed ID: 34737092
[TBL] [Abstract][Full Text] [Related]
4. Potential Cost-Effectiveness of Risk-Based Pancreatic Cancer Screening in Patients With New-Onset Diabetes.
Schwartz NRM; Matrisian LM; Shrader EE; Feng Z; Chari S; Roth JA
J Natl Compr Canc Netw; 2021 Jun; 20(5):451-459. PubMed ID: 34153945
[TBL] [Abstract][Full Text] [Related]
5. Endoscopy Is Cost-Effective for Gastric Cancer Screening After Successful Helicobacter pylori Eradication.
Kowada A
Dig Dis Sci; 2021 Dec; 66(12):4220-4226. PubMed ID: 33417196
[TBL] [Abstract][Full Text] [Related]
6. Is screening for pancreatic cancer in high-risk groups cost-effective? - Experience from a Danish national screening program.
Joergensen MT; Gerdes AM; Sorensen J; Schaffalitzky de Muckadell O; Mortensen MB
Pancreatology; 2016; 16(4):584-92. PubMed ID: 27090585
[TBL] [Abstract][Full Text] [Related]
7. Consensus guidelines in the management of branch duct intraductal papillary mucinous neoplasm: a cost-effectiveness analysis.
Huang ES; Gazelle GS; Hur C
Dig Dis Sci; 2010 Mar; 55(3):852-60. PubMed ID: 19834805
[TBL] [Abstract][Full Text] [Related]
8. Intraductal papillary mucinous neoplasms of the pancreas - a cost-effectiveness analysis of management strategies for the branch-duct subtype.
Aronsson L; Ansari D; Andersson B; Persson U; Fridhammar A; Andersson R
HPB (Oxford); 2018 Dec; 20(12):1206-1214. PubMed ID: 30064727
[TBL] [Abstract][Full Text] [Related]
9. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis.
Hoerger TJ; Harris R; Hicks KA; Donahue K; Sorensen S; Engelgau M
Ann Intern Med; 2004 May; 140(9):689-99. PubMed ID: 15126252
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of screening strategies to detect heart failure in patients with type 2 diabetes.
van Giessen A; Boonman-de Winter LJ; Rutten FH; Cramer MJ; Landman MJ; Liem AH; Hoes AW; Koffijberg H
Cardiovasc Diabetol; 2016 Mar; 15():48. PubMed ID: 27001409
[TBL] [Abstract][Full Text] [Related]
11. Branch-duct intraductal papillary mucinous neoplasm (IPMN): Are cyst volumetry and other novel imaging features able to improve malignancy prediction compared to well-established resection criteria?
Pozzi Mucelli RM; Moro CF; Del Chiaro M; Valente R; Blomqvist L; Papanikolaou N; Löhr JM; Kartalis N
Eur Radiol; 2022 Aug; 32(8):5144-5155. PubMed ID: 35275259
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention.
JAMA; 1998 Nov; 280(20):1757-63. PubMed ID: 9842951
[TBL] [Abstract][Full Text] [Related]
13. High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Cancer.
Majumder S; Philip NA; Singh Nagpal SJ; Takahashi N; Mara KC; Kendrick ML; Smyrk TC; Zhang L; Levy MJ; Gleeson FC; Petersen BT; Pearson RK; Topazian MD; Vege SS; Chari ST
Am J Gastroenterol; 2019 Mar; 114(3):524-529. PubMed ID: 30413822
[TBL] [Abstract][Full Text] [Related]
14. Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.
Veronesi G; Navone N; Novellis P; Dieci E; Toschi L; Velutti L; Solinas M; Vanni E; Alloisio M; Ghislandi S
Lung Cancer; 2020 May; 143():73-79. PubMed ID: 32234647
[TBL] [Abstract][Full Text] [Related]
15. Natural history of intraductal papillary mucinous neoplasm and non-neoplastic cyst: long-term imaging follow-up study.
Hisada Y; Nagata N; Imbe K; Takasaki Y; Sekine K; Tajima T; Yanase M; Fujimoto K; Akiyama J; Uemura N
J Hepatobiliary Pancreat Sci; 2017 Jul; 24(7):401-408. PubMed ID: 28512773
[TBL] [Abstract][Full Text] [Related]
16. Macrophage inhibitory cytokine-1/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort.
O'Neill RS; Emmanuel S; Williams D; Stoita A
World J Gastroenterol; 2020 Apr; 26(14):1660-1673. PubMed ID: 32327914
[TBL] [Abstract][Full Text] [Related]
17. The Clinical and Socio-Economic Relevance of Increased IPMN Detection Rates and Management Choices.
Budde C; Beyer G; Kühn JP; Lerch MM; Mayerle J
Viszeralmedizin; 2015 Feb; 31(1):47-52. PubMed ID: 26286668
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the Use of microRNA Blood Tests for Gastric Cancer Screening in a Stratified Population-Level Screening Program: An Early Model-Based Cost-Effectiveness Analysis.
Kapoor R; So JBY; Zhu F; Too HP; Yeoh KG; Yoong JS
Value Health; 2020 Sep; 23(9):1171-1179. PubMed ID: 32940235
[TBL] [Abstract][Full Text] [Related]
19. [MicroRNA expression pattern in intraductal papillary mucinous neoplasm].
Park YG; Lee KH; Lee JK; Lee KT; Choi DW; Choi SH; Heo JS; Jang KT; Lee EM; Kim JO; Min SY; Kim EJ
Korean J Gastroenterol; 2011 Oct; 58(4):190-200. PubMed ID: 22042419
[TBL] [Abstract][Full Text] [Related]
20. Novel Circulating miRNA Signatures for Early Detection of Pancreatic Neoplasia.
Vila-Navarro E; Duran-Sanchon S; Vila-Casadesús M; Moreira L; Ginès À; Cuatrecasas M; Lozano JJ; Bujanda L; Castells A; Gironella M
Clin Transl Gastroenterol; 2019 Apr; 10(4):e00029. PubMed ID: 31009404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
